Reviva Pharmaceuticals Holdings, Inc. (RVPH)
- Previous Close
1.7000 - Open
1.6900 - Bid 1.6500 x 200
- Ask 1.7500 x 200
- Day's Range
1.6400 - 1.7200 - 52 Week Range
1.6400 - 8.3000 - Volume
122,107 - Avg. Volume
274,337 - Market Cap (intraday)
47.601M - Beta (5Y Monthly) 0.05
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6500 - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.50
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
www.revivapharma.comRecent News: RVPH
Performance Overview: RVPH
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVPH
Valuation Measures
Market Cap
47.46M
Enterprise Value
42.71M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.30
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-115.85%
Return on Equity (ttm)
-556.38%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-39.26M
Diluted EPS (ttm)
-1.6500
Balance Sheet and Cash Flow
Total Cash (mrq)
23.37M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-13.99M
Research Analysis: RVPH
Company Insights: RVPH
RVPH does not have Company Insights